Search Results - "Evans, Tamasin"
-
1
Hypoalbuminaemia as a Prognostic Biomarker of First-Line Treatment Resistance in Metastatic Non-small Cell Lung Cancer
Published in Frontiers in nutrition (Lausanne) (01-10-2021)“…Introduction: Despite significant advances in systemic anticancer therapy (SACT) for non-small cell lung cancer (NSCLC), many patients still fail to respond to…”
Get full text
Journal Article -
2
Bilateral leg amputation following chemoradiation for squamous carcinoma of the anus
Published in Radiotherapy and oncology (01-10-2004)Get full text
Journal Article -
3
-
4
103 - Thymoma: a single centre, 10-year retrospective review
Published in Lung cancer (Amsterdam, Netherlands) (01-03-2022)Get full text
Journal Article -
5
Thymoma: a single centre, 10-year retrospective review
Published in Lung cancer (Amsterdam, Netherlands) (01-03-2022)Get full text
Journal Article -
6
Audit of cyclophosphamide/adriamycin/vincristine (CAV) chemotherapy use in Edinburgh Cancer Centre
Published in Lung cancer (Amsterdam, Netherlands) (01-06-2021)Get full text
Journal Article -
7
-
8
-
9
-
10
-
11
-
12
-
13
-
14
Adjuvant durvalumab post-chemoradiotherapy in stage III non-small cell lung cancer: experience from the Edinburgh Cancer Centre
Published in Lung cancer (Amsterdam, Netherlands) (01-03-2022)Get full text
Journal Article -
15
Biomarkers of systemic inflammation predict survival in stage III non-small cell lung cancer treated with chemoradiotherapy
Published in Lung cancer (Amsterdam, Netherlands) (01-03-2022)Get full text
Journal Article -
16
-
17
Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?
Published in Lung cancer (Amsterdam, Netherlands) (01-03-2022)Get full text
Journal Article -
18
124 - Real-world outcomes for patients with inoperable stage III non-small cell lung cancer: a prognostic role for albumin?
Published in Lung cancer (Amsterdam, Netherlands) (01-03-2022)Get full text
Journal Article -
19
-
20
Quality of life after breast-conserving therapy and adjuvant radiotherapy for non-low-risk ductal carcinoma in situ (BIG 3-07/TROG 07.01): 2-year results of a randomised, controlled, phase 3 trial
Published in The lancet oncology (01-05-2020)“…BIG 3-07/TROG 07.01 is an international, multicentre, randomised, controlled, phase 3 trial evaluating tumour bed boost and hypofractionation in patients with…”
Get full text
Journal Article